Business, Policy & Funding
Breaking news on Precision Oncology business, policy & funding.
Qlucore Expands Into Bladder Cancer Diagnostics With Lund University Partnership
The company expects that this work to develop and validate classifier models for bladder cancer will lead to a CE mark for its Qlucore Diagnostics software platform.
Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
The agency acknowledges its staff can't keep up with the volume of cell and gene therapy products and is looking to PDUFA VII for additional funds.Â
Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests
Tests like MDxHealth's SelectMDx, Bio-Techne's ExoDx Prostate, and various PSA scoring algorithms would be reimbursed if they pass a technical assessment.
Inceptor Bio Raises $37M in Series A Financing
The company will use the funds to advance development of its CAR-T, CAR-M, and CAR-NK programs into the clinic.